Iwona Ługowska

National Institute of Oncology — Hungary

Medicine · Health Sciences

32h-index7.9kcitations249works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(57), Sarcoma Diagnosis and Treatment(55), Lung Cancer Treatments and Mutations(26), CAR-T cell therapy research(23), Cutaneous Melanoma Detection and Management(19)

Publications248 total

Development of a Health-Related Quality of Life Tool for Adolescents and Young Adults With Cancer
JAMA Network Open·2025· 1 citedOpen Access
198MO MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001
Annals of Oncology·2025
Supplementary Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 8 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 9 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 10 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Figure 4 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 5 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Data from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025· 1 citedOpen Access
Supplementary Figure 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure 7 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 5 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
Table 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025Open Access
page 1 of 13Next →

Frequent Co-authors

Piotr Rutkowski(29), Jean‐Yves Blay(13), Paolo G. Casali(11), Javier Martín‐Broto(11), Angelo Paolo Dei Tos(11), Giovanni Grignani(11), Alessandro Gronchi(11), Antonio López–Pousa(11), Silvia Stacchiotti(11), Virginia Ferraresi(10), Piero Picci(9), Tomasz Świtaj(9), Patrick Schöffski(8), Paweł Teterycz(8), Hanna Koseła-Paterczyk(8), Judith V.M.G. Bovée(7), Anna Maria Frezza(7), Hans Gelderblom(7), Ian Judson(7), N. Abecassis(6)